Disease surveillance and reporting is critical to public health, enabling faster and better response to infectious disease outbreaks. As outlined in a previous blog, disease surveillance also plays an important role in developing vaccines for emerging infectious diseases more quickly, which, in turn, helps to limit the spread of these diseases.
Many emerging diseases are zoonotic in origin, meaning that they are transmitted by infected animals — and people who work in agriculture or live in rural settings are most likely to come into contact with animals carrying these diseases. With approximately half of their populations estimated to be rural, low- and middle-income countries (LMICs) are particularly at risk from emerging infectious diseases1. However, LMICs also face many challenges in regard to disease surveillance that high-income countries do not, and that call for unique solutions.
Challenges
One of the main challenges LMICs face in implementing robust disease surveillance is the lack of resources. By definition, LMICs have fewer financial resources than high-income countries, meaning that funding for surveillance is not always ideal or sustainable. However, human resources are often lacking as well, with high turnover for professionals engaged in disease surveillance. In these cases, inadequate training and uncoordinated supervision can combine with insufficient compensation and a high burden of work to demoralize personnel2.
Additionally, infrastructural concerns make disease surveillance and reporting more difficult. The internet, for example, empowers fast, powerful tools to communicate surveillance data. However, only about 35 percent of the people living in developing countries have access to the internet, introducing significant geographical gaps in the ability to use these tools for surveillance3. This is particularly detrimental in the remote and rural areas that are at notable risk for emerging infectious diseases, which may be located at great distance from other health centers.
Another problem is that passive surveillance, which is viewed as an inexpensive method to conduct surveillance on large areas, is not always suitable for rural LMIC populations. This method involves local hospitals, clinics and the like submitting reports to a health jurisdiction — but it depends on strong relationships with the surrounding community. When factors such as inaccessibility, distrust and regional conflict weaken these relationships, as may be the case for many rural LMIC populations, large portions of the population are excluded from reports4.
Solutions
While one of the more obvious approaches to supporting surveillance in LMICs is to provide more material resources, there are other paths that may make a positive difference as well.
One option is to support the increased training of physicians and veterinarians working in remote areas to support disease surveillance. With a strengthened understanding of zoonotic disease, including the presentation and diagnosis of known diseases, as well as the identification of potential novel zoonoses, clinicians will be better equipped to contribute to surveillance efforts. In particular, developing the skills to adapt to different disease scenarios, rather than learning purely technical skills, has been identified as an area that is particularly necessary.4 This training would help clinicians to be better prepared for a variety of situations. Additionally, larger numbers of trained staff would help to distribute workload and decrease the burden of work (and therefore stress) on any individual.
Another possibility to complement existing surveillance systems is the use of mobile phones to enable participatory surveillance, in which health officials can call or otherwise contact community members through mobile phones. This method has been used to track such emerging diseases as COVID-19 in resource-limited settings, enabled by the growing number of people in LMICs who own mobile phones.5 Such methods can help to mitigate the difficulties associated with geographic distance and the lack of internet access. However, this method does call for care to ensure that rural phone ownership is high enough in the country of interest, as otherwise data may skew towards urban areas at lower risk for contact with emerging infectious diseases.
A complex situation
Overcoming the barriers to improved disease surveillance in LMICs is a complex endeavor, and no single solution will definitively solve every difficulty. However, with numerous ways to support surveillance, our ability to detect and respond to emerging infectious diseases has significant potential to improve — so long as action is taken.
For more information on the role of disease surveillance and reporting in emerging infectious disease response, read the whitepaper, ‘Fortifying vaccines: Preparation and prevention against future infectious disease epidemics’.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel